预约演示
更新于：2025-10-31
Bromocriptine Mesylate
甲磺酸溴隐亭
更新于：2025-10-31
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H44BrN5O8S |
InChIKeyNOJMTMIRQRDZMT-GSPXQYRGSA-N |
CAS号22260-51-1 |
关联
83
项与 甲磺酸溴隐亭 相关的临床试验NCT03575000
Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Prediabetes
CTR20251772
甲磺酸溴隐亭片在健康受试者中随机、开放、单剂量、四周期、两序列、完全重复交叉的餐后状态下生物等效性试验
CTR20250991
甲磺酸溴隐亭片在健康受试者中随机、开放、单剂量、四周期、两序列、完全重复交叉的餐后状态下生物等效性试验
100 项与 甲磺酸溴隐亭 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸溴隐亭 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸溴隐亭 相关的专利（医药）
登录后查看更多信息
8,766
项与 甲磺酸溴隐亭 相关的文献（医药）2026-02-01JOURNAL OF CRITICAL CARE
Evaluation of bromocriptine for the reduction of fever in patients with acute neurologic injury: A retrospective cohort study
Article
作者: Sieg, Emily ; Livers, Kristen ; Campbell, Michelle ; Weitkamp, Lindsay ; Rhodes, Mikaela ; Daniels, Michael W
BACKGROUND/OBJECTIVE:
Fever is prevalent among patients with neurologic injury and has traditionally been treated with antipyretics and surface cooling modalities. Dopamine (D2) receptor agonists, such as bromocriptine, have shown a benefit for the treatment of central fever; however, there are currently no guidelines for the use of bromocriptine in this population. The purpose of this study was to evaluate the safety and efficacy of bromocriptine plus acetaminophen compared to acetaminophen alone for the treatment of fever in patients with acute neurologic injury.
METHODS:
This was a retrospective cohort study of patients admitted to the neurosciences intensive care unit (Neuro ICU) with an acute neurologic injury who received bromocriptine 5 mg every 8 h plus acetaminophen (BROMO) or acetaminophen alone (APAP) for the indication of fever. The primary outcome was reduction of temperature (°C) 72 h after initiation of bromocriptine and acetaminophen or acetaminophen alone.
RESULTS:
A total of 67 patients were included; 28 patients were included in the BROMO group and 39 patients in the APAP group. There was a significant reduction in temperature at 72 h in the BROMO group compared to the APAP group (-0.86 °C vs -0.39 °C, p = 0.017). No adverse effects were noted in either group.
CONCLUSION:
This study found that bromocriptine 5 mg every 8 h is safe when used in combination with acetaminophen for fever management among patients with neurologic injury. Additional prospective, multi-center studies are needed to further elucidate the role of bromocriptine in the treatment of fever in the Neuro ICU.
2026-01-01BRAIN BEHAVIOR AND IMMUNITY
Function and mechanism of dopamine receptor D2 (DRD2) in neuroinflammation and behavioral disorders in C57BL/6J mice infected with Toxoplasma gondii TgCtWh6 strain
Article
作者: Xie, Huanhuan ; Xie, Jinjing ; Xie, Xiaoman ; Zhou, Beibei ; Wang, Qi ; Hou, Yanhan ; Zhao, Guihua ; Li, Yanan ; Zhu, Wenju ; Xu, Chao ; Zhang, Xin ; Sun, Hang ; Yin, Kun ; Liu, Jiao ; Zhang, Junmei ; Dong, Hongjie
Toxoplasma gondii (T. gondii) is a globally distributed protozoan parasite, and its chronic infection has been closely associated with various neuropsychiatric disorders. However, the key susceptibility factors and mechanisms by which T. gondii manipulates host behaviors remain insufficiently understood. In this study, based on the comprehensive behavioral analyses including the AI HomeCage platform, and third-generation Nanopore-seq technology, we demonstrated that the T. gondii strain TgCtwh6 induces depression-like symptoms and cognitive impairments in hosts. These effects are linearly correlated with the expression levels of the host dopamine receptor D2 (DRD2). Furthermore, the behavioral abnormalities can be alleviated by treatment with the DRD2 agonist bromocriptine. Both in vivo and in vitro infection models revealed that the downregulation of DRD2 is significantly correlated with neuroinflammation and neuronal injury in the host central nervous system (CNS). Additionally, our findings suggest that the suppression of DRD2 may be regulated by enhanced RNA m6A modification following infection and may function through the DRD2/CRYAB/NF-κB signaling axis. These results emphasized the critical role of DRD2 in mediating T. gondii-induced neuroinflammation and neuropsychiatric abnormalities, providing novel insights into the development of therapeutic strategies for neuropsychiatric disorders associated with parasitic infections.
2025-12-01IJC Heart & Vasculature
Relationship between baseline right ventricular systolic function and left ventricular recovery at six-months of follow up among women with peripartum cardiomyopathy in Uganda
Article
作者: Sliwa, Karen ; Chakafana, Graham ; Okello, Emmy ; Nakimuli, Annettee ; Nabbaale, Juliet
Background:
LV recovery in Peripartum Cardiomyopathy (PPCM) depends on several baseline factors including left ventricular ejection fraction (LVEF), LV end-diastolic diameter (LVEDD), duration of symptoms. The role baseline RV function in LV recovery remains poorly described. This study sought to determine the relationship between baseline RV systolic function and LV recovery at six-months follow up among women with PPCM in Uganda.
Methods:
Prospective cohort study of 80 PPCM cases and 80 healthy matched controls observed over a 6-month period while on goal-directed medical therapy (GDMT). All enrolled participants had a 12-lead electrocardiography, echocardiography at baseline and at 6-months follow-up for assessment of LV systolic function using LV global longitudinal strain (LV GLS) and LV EF whereas RV systolic function was assessed using; fractional area change (FAC), tricuspid annular plane excursion (TAPSE), RV lateral wall S' (RV S'), fractional wall strain (FWS) and RV global longitudinal strain (RV GLS).
Results:
The mean data of cases included age of 33.6 ± 6.6 years, LVEF 35.7 ± 11.0 %, LV GLS -11.9 ± 4.7 % and RV GLS -14.7 ± 10.9 %, RV FAC 32.9 ± 13.5 %, Lat S' 10.6 ± 3.0 cm/s and RV FWS -17.1 ± 7.2 %. LV recovery occurred among 46.3 % cases. Factors which predicted LV recovery included heart rate and LVEDD.
Conclusion:
Under half of PPCM cases had LV recovery at six-months on GDMT and Bromocriptine. Baseline heart rate and LVEDD predicted LV recovery.
100 项与 甲磺酸溴隐亭 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2009-05-05 | |
| 不孕 | 中国 | - | 1999-07-28 |
| 高血压 | 日本 | 1993-01-19 | |
| 乳溢 | 日本 | 1978-08-01 | |
| 巨人症 | 日本 | 1978-08-01 | |
| 肢端肥大症 | 美国 | 1978-06-28 | |
| 高催乳素血症 | 美国 | 1978-06-28 | |
| 帕金森病 | 美国 | 1978-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 84 | (Cycloset (Bromocriptine-QR)) | 淵範餘遞築壓糧顧窪願(蓋顧顧遞獵顧廠醖艱壓) = 製襯繭製襯憲醖蓋鏇簾 簾簾廠齋醖築顧夢鹽觸 (壓鏇蓋廠繭網窪鏇壓觸, 構糧範範觸鏇選顧鏇窪 ~ 淵鹽餘廠願艱憲憲夢選) 更多 | - | 2021-12-10 | ||
Placebo (Placebo) | 淵範餘遞築壓糧顧窪願(蓋顧顧遞獵顧廠醖艱壓) = 壓艱繭蓋獵繭網製構壓 簾簾廠齋醖築顧夢鹽觸 (壓鏇蓋廠繭網窪鏇壓觸, 窪獵獵網遞餘糧獵簾網 ~ 膚窪遞廠構構積範築餘) 更多 | ||||||
临床2期 | 108 | Bromocriptine QR+Bromocriptine (Bromocriptine QR (Adolescents)) | 繭範醖顧齋遞築簾淵構(鹽範襯膚願餘窪網積願) = 憲製選鏇艱積淵製廠繭 壓艱艱願製鏇壓築鏇窪 (鏇鏇淵範築襯齋獵艱構, 5) 更多 | - | 2021-09-13 | ||
Bromocriptine QR (Bromocriptine QR (Adults)) | 繭範醖顧齋遞築簾淵構(鹽範襯膚願餘窪網積願) = 窪餘糧鬱願築獵繭鑰夢 壓艱艱願製鏇壓築鏇窪 (鏇鏇淵範築襯齋獵艱構, 5) 更多 | ||||||
临床1/2期 | 47 | (Acetaminophen) | 壓鏇醖鑰壓願窪鹹夢遞(鬱醖觸壓餘廠廠醖夢夢) = 獵遞齋齋製餘餘鹹選襯 餘獵憲獵繭鏇餘觸範壓 (觸鏇廠窪鑰壓衊蓋醖夢, 0.5) 更多 | - | 2021-06-24 | ||
(Bromocriptine and Acetaminophen) | 壓鏇醖鑰壓願窪鹹夢遞(鬱醖觸壓餘廠廠醖夢夢) = 繭製鹹製餘構蓋鬱膚繭 餘獵憲獵繭鏇餘觸範壓 (觸鏇廠窪鑰壓衊蓋醖夢, 0.6) 更多 | ||||||
N/A | - | Dose-Intensified Chemoradiation (Standard chemoradiation) | 製憲鏇觸膚淵築窪網網(壓願淵廠鑰鏇醖鹽衊廠) = 2 cases observed 醖膚廠憲繭壓膚網醖淵 (簾艱願鑰鹹選窪網鏇鏇 ) 更多 | - | 2020-11-01 | ||
临床4期 | 15 | insulin+metformin | 鑰選糧壓選範鏇構鹽窪(鹽鹽製選觸構襯壓鑰鹹) = 憲鹽選簾顧餘壓繭範製 襯簾蓋壓鏇膚鏇獵願範 (築夢夢遞襯範構襯遞蓋, 0.56) 更多 | - | 2019-09-16 | ||
N/A | 23,883 | 醖鹽廠膚夢鑰鹽襯憲顧(築築淵夢觸範壓壓鑰淵): hazard ratio = 1.32 (95% CI, 1.06 ~ 1.64), P-Value = 0.01 | - | 2019-09-02 | |||
临床4期 | 23 | 廠獵廠衊範鑰鏇鏇遞顧(遞憲衊壓遞鹽觸鬱製壓) = 簾願範醖衊鏇艱繭膚醖 齋窪蓋遞製構遞願齋遞 (衊範選製顧蓋獵淵蓋齋, 0.3) 更多 | - | 2019-06-21 | |||
临床2期 | 63 | 獵顧襯積積積憲衊襯衊(選鏇鹹繭遞衊艱網醖衊) = 觸鹹繭憲觸壓夢範餘簾 餘衊襯鹹夢繭襯窪鑰願 (醖糧積築選鑰膚襯夢衊 ) | - | 2017-09-14 | |||
獵顧襯積積積憲衊襯衊(選鏇鹹繭遞衊艱網醖衊) = 獵範鑰簾範鹹獵衊製積 餘衊襯鹹夢繭襯窪鑰願 (醖糧積築選鑰膚襯夢衊 ) | |||||||
临床3期 | 60 | Bromocriptine-QR | 獵壓積網鬱醖遞醖鏇積(積鬱選鏇淵繭醖憲獵蓋) = 艱願構艱獵襯襯襯顧積 齋簾願壓襯網鹹構餘襯 (積選鏇鑰夢壓鬱淵廠網 ) 更多 | - | 2017-05-01 | ||
临床3期 | 1,834 | Bromocriptine-QR | 壓鬱蓋網範遞淵範蓋襯(顧製衊範艱壓鑰選淵壓): HR = 0.52 (95% CI, 0.28 ~ 0.98) 更多 | 积极 | 2015-01-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用